文献速递肝病

台湾HBV/HCV合并感染者接受直接抗病毒药物治疗后HBV相关结局分析

Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
PubMed 文献 · J Hepatol · 2020-02-14

该研究纳入79例接受DAA治疗的HBV/HCV合并感染者(其中13例同时接受抗HBV核苷(酸)类似物治疗),连续监测HBsAg和HBV DNA。结果显示DAA治疗期间HBsAg水平下降,但治疗后12个月回升;10.1%的患者出现HBsAg清除,38.0%出现HBV再激活。治疗前HBsAg≤10 IU/ml者HBsAg清除率更高且再激活风险更低。未接受NUC治疗的6例患者发生HBV相关临床再激活,其中4例肝硬化患者中3例发展为肝衰竭、2例死亡。与未治疗的HBV单一感染者相比,无NUC预防的合并感染者HBV再激活风险显著更高(HR 6.59)。结论认为DAA治疗的合并感染者HBsAg清除率较高但再激活风险也高,肝硬化患者应预防性抗HBV治疗。

要点

  • DAA治疗的HBV/HCV合并感染者HBsAg清除率10.1%,HBV再激活率38.0%。
  • 治疗前HBsAg≤10 IU/ml者HBsAg清除率更高(HR 8.52)且再激活风险更低(HR 2.88)。
  • 肝硬化合并感染者无论基线HBV DNA水平均应预防性抗HBV治疗。

核心结论

  • DAA治疗的HBV/HCV合并感染者HBsAg清除率较高,尤其治疗前HBsAg滴度低者,但HBV再激活风险也较高,尤其治疗前HBsAg滴度高者。
  • 肝硬化患者无论基线HBV DNA水平如何,预防性抗HBV治疗是必要的。

研究设计与样本

  • 研究纳入79例接受DAA治疗的HBV/HCV合并感染者,其中13例同时接受抗HBV核苷(酸)类似物治疗。
  • 连续监测血清HBsAg和HBV DNA水平,随访平均11.1个月。

主要发现

  • HBsAg水平从基线中位73.3 IU/ml降至DAA治疗结束时16.2 IU/ml,治疗后12个月升至94.1 IU/ml。
  • 随访期间8例(10.1%)发生HBsAg清除,30例(38.0%)发生HBV再激活,12个月累积发生率分别为10.3%和40.4%。
  • 治疗前HBsAg≤10 IU/ml者相比>10 IU/ml者,HBsAg清除率显著更高(HR 8.52;95%CI 1.048-69.312),HBV再激活风险更低(HR 2.88;95%CI 1.057-7.844)。
  • 6例未接受NUC治疗的患者发生HBV相关临床再激活,其中4例为肝硬化,3例肝硬化患者发展为肝衰竭,2例死亡。
  • 与未治疗的HBV单一感染者相比,无NUC预防的合并感染者HBsAg清除率相似,但HBV再激活风险显著更高(HR 6.59;95%CI 2.488-17.432)。

临床怎么用

  • 对HBV/HCV合并感染者接受DAA治疗时,应监测HBsAg和HBV DNA水平以评估再激活风险。
  • 治疗前HBsAg≤10 IU/ml者HBsAg清除可能性更高,可加强监测。
  • 肝硬化合并感染者无论基线HBV DNA水平均应预防性使用抗HBV治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The outcome of HBV infection, including the dynamics of HBsAg and HBV virological reactivation, among patients coinfected with HCV receiving direct-acting antivirals (DAAs) remains unclear. Thus, we aimed to analyze HBV-related outcomes in these patients. METHODS: Serial HBsAg and HBV DNA levels were measured in 79 HBV/HCV-coinfected patients receiving DAAs (13 receiving anti-HBV nucleot(s)ide analog [NUC] therapy simultaneously). The endpoints included HBsAg dynamics and seroclearance, HBV reactivation (HBV DNA >1 log increase or >100 IU/ml if undetectable at baseline) and HBV-related clinical reactivation. RESULTS: HBsAg levels declined from a median of 73.3 IU/ml at baseline to 16.2 IU/ml at the end-of-DAA treatment and increased to 94.1 IU/ml at 12 months post-treatment. During a mean 11.1-months of follow-up, 8 (10.1%) patients experienced HBsAg seroclearance and 30 (38.0%) HBV reactivation (12-month cumulative incidence, 10.3% and 40.4%, respectively). Patients with pre-treatment HBsAg ≤10 IU/ml had a significantly higher rate of HBsAg seroclearance (hazard ratio [HR] 8.52; 95% CI 1.048-69.312) and lower risk of HBV reactivation than those with pre-treatment HBsAg >10 IU/ml (HR 2.88; 95% CI 1.057-7.844) in multivariate analyses. Six patients (4 cirrhotics) not receiving NUC therapy experienced HBV-related clinical reactivation; 3 of the 4 cirrhotics developed liver failure and 2 died despite immediate NUC therapy. Compared to untreated HBV-monoinfected patients, HBV/HCV-coinfected patients without NUC prophylaxis had a similar rate of HBsAg seroclearance, but a significantly higher risk of HBV reactivation following DAA therapy (HR 6.59; 95% CI 2.488-17.432). CONCLUSIONS: DAA-treated HBV/HCV-coinfected patients had significantly higher rates of HBV seroclearance, particularly among those with low pre-treatment HBsAg titer, but were at higher risk of HBV reactivation, particularly among those with higher pre-treatment HBsAg titer. Prophylactic anti-HBV therapy is essential for cirrhotic patients, irrespective of baseline HBV DNA levels. LAY SUMMARY: We studied outcomes relating to hepatitis B virus (HBV) in patients coinfected with both hepatitis B and C. Patients receiving direct-acting antiviral treatment for hepatitis C were more likely to experience seroclearance (or functional cure of HBV), but were also more likely to experience HBV reactivation, which can lead to hepatitis, liver failure and death. In coinfected cirrhotic patients being treated for HCV, prophylactic treatment for HBV is mandatory.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yeh ML, Huang CF, Huang CI, et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol. 2020. PMID: 32061869. doi:10.1016/j.jhep.2020.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。